We tested three serotonin antagonists--lysergic acid diethylamide (LSD), 2-bromolysergic acid diethylamide (BOL), and cinanserin--for effects on experimental spinal cord ischemia in the rabbit. Blood flow to spinal cord was obstructed. Drugs were administered before or after initiation of occlusion, and flow was later restored. When LSD was given 5 minutes after the onset of occlusion, the duration of ischemia required to produce neurologic abnormality was prolonged, but this protection was temporary. BOL and cinanserin treatment 5 minutes after the onset of ischemia was beneficial because neurologic improvement was permanent, and pretreatment with these drugs also markedly reduced damage. Therefore, several serotonin antagonists can prevent or reduce spinal cord damage when administered before or after the onset of ischemia.

No abstract

No abstract

Introduction: Prescribing patterns and suboptimal adherence present methodological challenges for real-world head-to-head comparisons of ticagrelor and clopidogrel in intent-to-treat studies. The aim of this study was to compare ticagrelor and clopidogrel in an on-treatment population. Methods: This retrospective cohort study used the Optum TM Clinformatics TM database to identify patients with acute coronary syndrome (ACS) discharged on ticagrelor or clopidogrel between January 1, 2012 and September 30, 2019. The primary end point was hospitalization for myocardial infarction (MI); the secondary end point was hospitalization for major bleeding. The ticagrelor and clopidogrel cohorts were balanced by propensity score matching (PSM) 1:3 for demographic and clinical characteristics. Outcomes were ascertained from day 31 until day 365 or end of follow-up.Results: Of 339,387 patients with ACS, 14,110 ticagrelor-and 57,482 clopidogrel-treated patients met the study criteria. After PSM, 13,373 ticagrelor-and 29,656 clopidogrel-treated patients provided 4945 and 13,895 patientyears of data, respectively, for the primary end point. Hospitalization for MI was significantly lower in the ticagrelor compared to the clopidogrel cohort (2.22 vs. 3.52 per 100 patientyears; 36.8% relative risk reduction [RRR]; P \ 0.0001). Hospitalization for major bleeding was similar in the ticagrelor and clopidogrel cohorts (2.04 vs. 2.06 per 100 patient-years; 1.1% RRR, P = 0.9214). Conclusions: In this real-world on-treatment analysis, hospitalization for MI was significantly lower with ticagrelor compared to clopidogrel, with similar rates of hospitalization for major bleeding. Study findings underscore the importance of being on the appropriate guidelinerecommended therapy and support the use of ticagrelor over clopidogrel.

The society for cardiovascular angiography and interventions (SCAI) think tank is a collaborative venture that brings together interventional cardiologists, administrative partners, and select members of the cardiovascular industry community for high‐level field‐wide discussions. The 2020 think tank was organized into four parallel sessions reflective of the field of interventional cardiology: (a) coronary intervention, (b) endovascular medicine, (c) structural heart disease, and (d) congenital heart disease (CHD). Each session was moderated by a senior content expert and co‐moderated by a member of SCAI's emerging leader mentorship program. This document presents the proceedings to the wider cardiovascular community in order to enhance participation in this discussion, create additional dialogue from a broader base, and thereby aid SCAI and the industry community in developing specific action items to move these areas forward.